News | October 22, 2012

FDA Approves Gore Septal Occluder for Use in Gore REDUCE Clinical Study

Gore invests latest technology in PFO closure study for cryptogenic stroke patients

Gore Helex Septal Occcluder Clinical Study

October 22, 2012 — W. L. Gore & Associates announced that the U.S. Food and Drug Administration (FDA) has approved the use of the new Gore septal occluder for inclusion in the Gore REDUCE clinical study. Gore is introducing this latest technology in its Gore REDUCE clinical study for prevention of recurrent stroke in patent foramen ovale (PFO) patients. The study is designed to demonstrate that PFO closure with the Gore device plus antiplatelet medical management reduces the risk of recurrent stroke or imaging-confirmed transient ischemic attack (TIA) when compared to antiplatelet medical management alone. The prospective, randomized, multicenter, multinational trial includes up to 80 investigational sites in the United States, Europe and Canada.

The new Gore device received CE mark in June 2011 for the indication of PFO and atrial septal defect (ASD) closure. Dr. Lars Sondergaard, Nordic Region Cardiology principal investigator for the Gore REDUCE clinical study, performed the first European procedures using the Gore device. “We have seen great success with the GORE septal occluder since we completed the first implant. The device provides ease of deployment and confidence through design for the patient’s well-being,” said Sondergaard.

Leveraging more than 13 years of clinical experience with septal occluders, the Gore septal occluder is a next-generation device that successfully integrates innovative material and design to yield a treatment option whose discs are intended to conform to the anatomy of the individual patient. The Gore device is comprised of a five-wire support frame covered with a thin ePTFE, patch-like material. The soft, strong and conformable membrane is intended to improve closure performance, providing an open microstructure to encourage fast controlled tissue ingrowth. This structure is designed to help enhance the safety of the procedure, one of several characteristics that will be investigated in the Gore REDUCE clinical study.

For more information:

Related Content

FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Videos | Structural Heart Occluders | June 16, 2016
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcat
PFO occluder, amplatzer
Feature | Structural Heart Occluders | May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Overlay Init